Etanercept for the treatment of rheumatoid arthritis

Zhao, Sizheng ORCID: 0000-0002-3558-7353, Mysler, Eduardo and Moots, Robert J ORCID: 0000-0001-7019-6211 (2018) Etanercept for the treatment of rheumatoid arthritis. IMMUNOTHERAPY, 10 (6). pp. 433-445.

Text Etanercept main text PR clean.docx - Author Accepted Manuscript Download (288kB)

Abstract

Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease. Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, function, quality of life and mortality for these patients. It is structurally distinct from other TNF inhibitors and thus has desirable profiles for immunogenicity, drug survival and infection rate. With the increasing number of etanercept biosimilars, there will likely be a resurgence of their prescription. This article reviews the pharmacology, efficacy and safety of the etanercept reference product, and its biosimilars, in the context of RA treatment.

Item Type:	Article
Uncontrolled Keywords:	anti-TNF, biosimilar, efficacy, Enbrel, etanercept, GP2015, pharmacology, rheumatoid arthritis, safety, SB4
Depositing User:	Symplectic Admin
Date Deposited:	08 Jan 2019 14:43
Last Modified:	19 Jan 2023 06:33
DOI:	10.2217/imt-2017-0155
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3021465